<VariationArchive VariationID="1456662" VariationName="NM_000531.6(OTC):c.653_663del (p.Ala218fs)" VariationType="Deletion" Accession="VCV001456662" Version="4" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-20" DateCreated="2022-03-28" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1454764" VariationID="1456662">
      <GeneList>
        <Gene Symbol="OTC" FullName="ornithine transcarbamylase" GeneID="5009" HGNC_ID="HGNC:8512" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xp11.4</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="38327684" stop="38422928" display_start="38327684" display_stop="38422928" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="38211735" stop="38280702" display_start="38211735" display_stop="38280702" Strand="+" />
          </Location>
          <OMIM>300461</OMIM>
          <Haploinsufficiency last_evaluated="2012-06-28" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=OTC">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2012-06-28" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=OTC">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000531.6(OTC):c.653_663del (p.Ala218fs)</Name>
      <CanonicalSPDI>NC_000023.11:38403727:AGCTACTCCAAAG:AG</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xp11.4</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="38403728" stop="38403738" display_start="38403728" display_stop="38403738" variantLength="11" positionVCF="38403727" referenceAlleleVCF="CAGCTACTCCAA" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="38262981" stop="38262991" display_start="38262981" display_stop="38262991" variantLength="11" positionVCF="38262980" referenceAlleleVCF="CAGCTACTCCAA" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>A218fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_846" sequenceAccession="LRG_846">
            <Expression>LRG_846:g.56248_56258del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_846t1" sequenceAccession="LRG_846t1">
            <Expression>LRG_846t1:c.653_663del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_846p1" sequenceAccession="LRG_846p1" change="p.Ala218fs">
            <Expression>LRG_846p1:p.Ala218fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.38262983_38262993del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.38262983_38262993del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.38403730_38403740del" Assembly="GRCh38">
            <Expression>NC_000023.11:g.38403730_38403740del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008471.1" sequenceAccession="NG_008471" sequenceVersion="1" change="g.56248_56258del">
            <Expression>NG_008471.1:g.56248_56258del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000531.6" sequenceAccession="NM_000531" sequenceVersion="6" change="c.653_663del" MANESelect="true">
            <Expression>NM_000531.6:c.653_663del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000522.3" sequenceAccession="NP_000522" sequenceVersion="3" change="p.Ala218fs">
            <Expression>NP_000522.3:p.Ala218fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2147342791" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000531.6(OTC):c.653_663del (p.Ala218fs) AND Ornithine carbamoyltransferase deficiency" Accession="RCV001951259" Version="3">
        <ClassifiedConditionList TraitSetID="3053">
          <ClassifiedCondition DB="MedGen" ID="C0268542">Ornithine carbamoyltransferase deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-10-06" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-10-06" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-03-28" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10946359</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16786505</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3053" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3120" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Ornithine carbamoyltransferase deficiency</ElementValue>
                <XRef ID="Ornithine+transcarbamylase+deficiency/5412" DB="Genetic Alliance" />
                <XRef ID="MONDO:0010703" DB="MONDO" />
                <XRef ID="80908008" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">OTC deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ornithine Carbamoyltransferase Deficiency Disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ornithine transcarbamylase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">ORNITHINE TRANSCARBAMYLASE DEFICIENCY, HYPERAMMONEMIA DUE TO</ElementValue>
                <XRef Type="MIM" ID="311250" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">OTCD</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8391" />
                <XRef ID="8391" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Ornithine transcarbamylase (OTC) deficiency can occur as a severe neonatal-onset disease in males (but rarely in females) and as a post-neonatal-onset (also known as "late-onset" or partial deficiency) disease in males and females. Males with severe neonatal-onset OTC deficiency are asymptomatic at birth but become symptomatic from hyperammonemia in the first week of life, most often on day two to three of life, and are usually catastrophically ill by the time they come to medical attention. After successful treatment of neonatal hyperammonemic coma these infants can easily become hyperammonemic again despite appropriate treatment; they typically require liver transplant to improve quality of life. Males and heterozygous females with post-neonatal-onset (partial) OTC deficiency can present from infancy to later childhood, adolescence, or adulthood. No matter how mild the disease, a hyperammonemic crisis can be precipitated by stressors and become a life-threatening event at any age and in any situation in life. For all individuals with OTC deficiency, typical neuropsychological complications include developmental delay, learning disabilities, intellectual disability, attention-deficit/hyperactivity disorder, and executive function deficits.</Attribute>
                <XRef ID="NBK154378" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301396</ID>
                <ID Source="BookShelf">NBK1217</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24006547</ID>
                <ID Source="BookShelf">NBK154378</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Decreased-Citrulline.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased Citrulline, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Decreased-Citrulline-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Decreased Citrulline, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/OTC-Deficiency-Transition.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Transition to Adult Health Care ACT Sheet, Ornithine Transcarbamylase (OTC) deficiency, 2012</CitationText>
              </Citation>
              <XRef ID="664" DB="Orphanet" />
              <XRef ID="C0268542" DB="MedGen" />
              <XRef ID="MONDO:0010703" DB="MONDO" />
              <XRef Type="MIM" ID="311250" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4260832" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="14879363|MedGen:C0268542" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002242650" DateUpdated="2024-02-20" DateCreated="2022-03-28" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-10-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10946359</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16786505</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant has not been reported in the literature in individuals affected with OTC-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Ala218Glyfs*3) in the OTC gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in OTC are known to be pathogenic (PMID: 10946359, 16786505).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="OTC" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.38262981_38262991del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268542" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12506961</SubmissionName>
          <SubmissionName>SUB14200279</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4260832" TraitType="Disease" MappingType="XRef" MappingValue="C0268542" MappingRef="MedGen">
        <MedGen CUI="C0268542" Name="Ornithine carbamoyltransferase deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

